Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, September 19, 2016

New Ampyra Trial Bolsters MS Efficacy Claims


Click here to receive MS news via e-mail

Walking ability, as reported by patients, significantly improved

LONDON -- The only drug approved to improve mobility in multiple sclerosis (MS) patients -- dalfampridine (Ampyra) -- has long been plagued by doubts about its efficacy, but a randomized trial reported here suggests that the drug genuinely does produce clinically significant improvements in walking ability.

In the 633-patient, 24-week study, 43.2% of those receiving dalfampridine (known simply as fampridine outside the U.S.) showed improvement of at least 8 points on the 12-point, patient-reported MS Walking Scale (MSWS), compared with 33.6% of the placebo group (P=0.006), reported Jeremy Hobart, BSc, PhD, of Plymouth University in England.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: